Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the Chicago metropolitan area: Impact of timing and surge capacity

Biosecurity and Bioterrorism

Volumn 10, Issue 3, 2012, Pages 264-279

  Kyriacou, Demetrios N ^a   Dobrez, Debra ^e   Parada, Jorge P ^f   Steinberg, Justin M ^a   Kahn, Adam ^b   Bennett, Charles L ^c,d   Schmitt, Brian P ^g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b 3E 127 Brody Building   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACILLUS ANTHRACIS; BIOLOGICAL ACCIDENT; BIOLOGICAL WARFARE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; EMERGENCY HEALTH SERVICE; HUMAN; STATISTICS; TIME; UNITED STATES; VACCINATION;

ANTHRAX; ANTHRAX VACCINES; ANTIBIOTIC PROPHYLAXIS; BACILLUS ANTHRACIS; BIOHAZARD RELEASE; BIOTERRORISM; CHICAGO; COST-BENEFIT ANALYSIS; EMERGENCY MEDICAL SERVICES; HUMANS; TIME FACTORS; VACCINATION;

EID: 84866280388     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2011.0105     Document Type: Article

References (81)

1. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002. JAMA 2002;287:2236-2252.
2. Brachman PS. Bioterrorism: an update with a focus on anthrax. Am J Epidemiol 2002;155:981-987. (Pubitemid 34587481)
3. Inglesby TV, O'Toole T, Henderson DA. Preventing the use of biological weapons: improving response should prevention fail. Clin Infect Dis 2000;30:926-929. (Pubitemid 32250332)
4. World Health Organization. Health Aspects of Chemical and Biological Weapons: Report of a WHO Group of Consultants. Geneva, Switzerland: World Health Organization; 1970.
5. Office of Technology Assessment, US Congress. Proliferation of Weapons of Mass Destruction: Assessing the Risks. Washington, DC: Office of Technology Assessment; 1993. http://www.au.af.mil/au/awc/awcgate/ota/9341.pdf. Accessed June 7, 2012.
6. Graham B, Talent J, Allison G, et al. World at Risk: The Report of the Commission on the Prevention of WMD Proliferation and Terrorism. New York: Vintage Books; 2008.
7. Swartz MH. Recognition and management of anthrax-an update. N Engl J Med 2001;345:1621-1626.
8. US Centers for Disease Control and Prevention. Cities Readiness Initiative. 2010. http://www.bt.cdc.gov/cri/. Accessed June 7, 2012.
9. Buehler JW, Hopkins RS, Overhage JM, Sosin DM, Tong V; CDC Working Group. Framework for evaluating public health surveillance systems for early detection of outbreaks. MMWR Recomm Rep 2004;53(RR-5):1-11.
10. Eitzen EM. Framing the issues. In: Knobler SL, Mahmoud AAF, Pray LA, eds. Biological Threats and Terrorism-Assessing the Science and Response Capabilities. Washington, DC: National Academy Press, Institute of Medicine; 2002.
11. Wein LM, Craft DL, Kaplan EH. Emergency response to an anthrax attack. Proc Natl Acad Sci USA 2003;100: 4346-4351. (Pubitemid 36418205)
12. Brookmeyer R, Johnson E, Bollinger R. Public health vaccination policies for containing an anthrax outbreak. Nature 2004;432:901-904. (Pubitemid 40037150)
13. Brookmeyer R, Johnson E, Bollinger R. Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc Natl Acad Sci USA 2003;100:10129-10132. (Pubitemid 37087079)
14. Wein LM, Craft DL. Evaluation of public health interventions for anthrax: a report to the secretary's council on public health preparedness. Biosecur Bioterror 2005;3:348-356. (Pubitemid 43799285)
15. Baccam P, Boechler M. Public health response to an anthrax attack: an evaluation of vaccination policy options. Biosecur Bioterror 2007;5:26-34. (Pubitemid 46769864)
16. Braithwaite RS, Fridsma D, Roberts MS. The cost-effectiveness of strategies to reduce mortality from an intentional release of aerosolized anthrax spores. Med Decis Making 2006;26:182-193.
17. Schneider H. Protecting public health in the age of bioterrorism surveillance: is the price right? J Environ Health 2005;68:9-13. (Pubitemid 41720675)
18. Kaufmann AF,Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable? Emerg Infect Dis 1997;3:83-94. (Pubitemid 127431666)
19. St John R, Finlay B, Blair C. Bioterrorism in Canada: an economic assessment of prevention and postattack response. Can J Infect Dis 2001;12:275-284. (Pubitemid 33111425)
20. Fowler RA, Sanders GD, Bravata DM, et al. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann Intern Med 2005;142:601-610. (Pubitemid 40529956)
21. GoldM,Sigel J,Russell L,WeinsteinM, eds.Cost-effectiveness in Health andMedicine.NewYork:OxfordUniversity Press; 1996.
22. Geier MR, Geier DA. Gastrointestinal adverse reactions following anthrax vaccination: an analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Hepatogastroenterology 2004;51:762-767. (Pubitemid 38590959)
23. Enstone JE, Wale MC, Nguyen-Van-Tam JS, Pearson JC. Adverse medical events in British service personnel following anthrax vaccination. Vaccine 2003;21(13-14): 1348-1354. (Pubitemid 36263175)
24. Hoffman K, Costello C, Menich M, Grabenstein JD, Engler RJ. Using a structured medical note for determining the safety profile of anthrax vaccine for US soldiers in Korea. Vaccine 2003;21(27-30):4399-4409. (Pubitemid 37130279)
25. US Centers for Disease Control and Prevention. Surveillance for adverse events associated with anthrax vaccination: US Department of Defense, 1998-2000. MMWR Morb Mortal Wkly Rep 2000;49:341-345.
26. Tierney BC, Martin SW, Franzke LH, et al. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax. Clin Infect Dis 2003;37(7):905-911. (Pubitemid 37267204)
27. Friedlander AM, Pittman PR, Parker GW. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 1999;282(22):2104-2106.
28. Wright GG, Green TW, Kanode RG. Studies on immunity in anthrax, V: immunizing activity of alum-precipitated protective antigen. J Immunol 1954;73(6):387-391.
29. US Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. MMWR Morb Mortal Wkly Rep 2001;50(44):973-976.
30. Shepard CW, Soriano-Gabarro M, Zell ER, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002;8(10):1124-1132. (Pubitemid 35257005)
31. Tengs TO, Wallace A. One thousand health-related qualityof-life estimates. Med Care 2000;38(6):583-637.
32. Reissman DB, Whitney EA, Taylor TH Jr, et al. One-year health assessment of adult survivors of Bacillus anthracis infection. JAMA 2004;291(16):1994-1998. (Pubitemid 38544281)
33. Roos R. HHS buys anthrax vaccine for civilian stockpile [news release]. May 5, 2005. Center for Infectious Disease Research and Policy. http://www.cidrap.umn.edu/cidrap/content/bt/anthrax/news/may0605anthrax.html. Accessed June 7, 2012.
34. American Medical Association. Current Procedural Terminology. https://catalog.ama-assn.org/Catalog/product/product-detail. jsp?productId = prod1990004. Accessed June 7, 2012.
35. Fleming T, ed. 2005 Redbook: Pharmacy's Fundamental Reference. Montvale, NJ: Thompson PDR Publishing; 2005.
36. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorismrelated inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001;7:933-944. (Pubitemid 33115771)
37. Barakat LA, Quentzel HL, Jernigan JA, et al. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002;287:863-868. (Pubitemid 34252033)
38. US Centers for Disease Control and Prevention. Inhalation anthrax associated with dried animal hides-Pennsylvania and New York City, 2006. MMWR Morb Mortal Wkly Rep 2006;55(10):280-282.
39. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb- emergency.jsp. Accessed June 7, 2012.
40. Bureau of Labor Statistics. Occupational Employment Statistics. http://www.bls.gov/oes/current/oes292041.htm. Accessed June 7, 2012.
41. Bureau of Census. http://www.census.gov/population/pro jections/SummaryTabA1.xls. Accessed June 7, 2012.
42. US Centers for Disease Control and Prevention. National Vital Statistics System. http://205.207.175.93/vitalstats/ReportFolders/ReportFolders.aspx?IF- ActivePathName = P/Populations. Accessed June 7, 2012.
43. US Centers for Disease Control and Prevention. National Vital Statistics Reports. http://www.cdc.gov/nchs/products/nvsr.htm. Accessed June 7, 2012.
44. Social Science Data Analysis Network. http://www.censusscope. org/us/s17/chart-migration.html. Accessed June 7, 2012.
45. State of Illinois Department of Public Health. Annual Hospital Questionnaire for 2005.
46. US Department of Health and Human Services. Aerosolized Anthrax Response Playbook. http://www.phe.gov/preparedness/planning/playbooks/anthrax/Pages/ default.aspx. Accessed June 7, 2012.
47. Elashoff RM, Li G, Li N. A joint model for longitudinal measurements and survival data in the presence of multiple failure types. Biometrics 2007;64(3):762-771.
48. Chang CM, Lin WC, Kuo HS, Yen MF, Chen TH. Estimation and prediction system for multistate disease process: application to analysis of organized screening regime. J Eval Clin Pract 2007;13(6):867-881. (Pubitemid 350125474)
49. Nathoo FS, Dean CB. Spatial multistate transitional models for longitudinal event data. Biometrics 2008;64(1):271-279. (Pubitemid 351316854)
50. Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006; 144(4):270-280. (Pubitemid 46768211)
51. Brookmeyer R, Johnson E, Barry S. Modeling the incubation period of anthrax. Stat Med 2005;24(4):531-542.
52. Kyriacou DN, Stein AC, Yarnold PR, et al. Clinical predictors of bioterrorism-related inhalational anthrax. Lancet 2004;364(9s432):449-452. (Pubitemid 39036893)
53. Kyriacou DN, Yarnold PR, Stein AC, et al. Discriminating inhalational anthrax from community-acquired pneumonia using chest radiograph findings and a clinical algorithm. Chest 2007;131(2):489-496. (Pubitemid 46280410)
54. Stickney CP,Weil RL. Financial Accounting: An Introduction to Concepts, Methods, and Uses. 12th ed. Mason, OH: Thompson South-Western; 2006.
55. Kaji AH, Lewis RJ. Hospital disaster preparedness in Los Angeles County. Acad Emerg Med 2006;13(11):1198-1203. (Pubitemid 44740501)
56. Niska RW, Burt CW. Emergency response planning in hospitals, United States: 2003-2004. AdvanceData 2007;(391):1-13.
57. Rebmann T, Carrico R, English JF. Hospital infectious disease emergency preparedness: a survey of infection control professionals. Am J Infect Control 2007;35(1):25-32. (Pubitemid 46185715)
58. Hanley M, Bogdan GM. Mechanical ventilation in mass casualty scenarios, augmenting staff: Project XTREME. Respiratory Care 2008;53(2):176-189.
59. Rubinson L, Nuzzo JB, Talmor DS, O'Toole T, Kramer BR, Inglesby TV. Augmentation of hospital critical care capacity after bioterrorist attacks or epidemics: recommendations of the Working Group on Emergency Mass Critical Care. Crit Care Med 2005;33(10):2393-2403. (Pubitemid 41437496)
60. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field evaluation of a human anthrax vaccine. Am J Public Health 1962;52(4):632-645.
61. US Centers for Disease Control and Prevention. Strategic National Stockpile (SNS). Updated March 8, 2012. http://emergency.cdc.gov/stockpile/ index.asp. Accessed June 7, 2012.
62. Hupert N, Mushlin AI, Callahan MA. Modeling the public health response to bioterrorism: using discrete event simulation to design antibiotic centers. Med Decis Making 2002; 22:S17-25.
63. Agency for Healthcare Research and Quality. Computer Staffing Model for Bioterrorism Response Version 2.0 BERM. http://archive.ahrq.gov/research/ biomodel.htm. Accessed June 7, 2012.
64. US Centers for Disease Control and Prevention. Point of Dispensing (POD) Standards, April 2008. http://health.mo. gov/emergencies/sns/pdf/12- PODStandards.pdf. Accessed June 7, 2012.
65. Bureau of Labor Statistics. Consumer Price Index http://www.bls.gov/cpi/ home.htm#data. May 13, 2008.
66. US Centers for Disease Control and Prevention. Surveillance for adverse events associated with anthrax vaccination-U.S. Department of Defense, 1998-2000. MMWR Morb Mortal Wkly Rep 2000;49(16):341-345.
67. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005;187:106-108. (Pubitemid 41139681)
68. Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res 2006;6:52.
69. Bravata DM, Zaric GS, Holty JE, et al. Reducing mortality from anthrax bioterrorism: strategies for stockpiling and dispensing medical and pharmaceutical supplies. Biosecur Bioterror 2006;4:244-262. (Pubitemid 44526071)
70. Zaric GS, Bravata DM, Holty JE, McDonald KM, Owens DK, Brandeau ML. Modeling the logistics of response to anthrax bioterrorism. Med Decis Making 2008;28:332-350. (Pubitemid 351713300)
71. Guidi-Rontani C, Mock M. Macrophage interactions. Curr Top Microbiol Immunol 2002;271:115-141. (Pubitemid 34847397)
72. Dixon TC, Fadl AA, Koehler TM, Swanson JA, Hanna PC. Early bacillus anthracis-macrophage interactions: intracellular survival and escape. Cell Microbiol 2000;2(6): 453-463. (Pubitemid 32049317)
73. Ivins BE, Pitt ML, Fellows PF, et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalational anthrax in rhesus macaques. Vaccine 1998;16(11-12): 1141-1148. (Pubitemid 28307883)
74. Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT. Patterns of antibody response in humans to anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 2006;24(17):3654-3660.
75. US Centers for Disease Control and Prevention. Occupational health guidelines for remediation workers at Bacillus anthracis-contaminated sites-United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2002;51(35): 786-789.
76. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond) 1956;54(1):28-36.
77. Friedlander AM, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993;167(5):1239-1243. (Pubitemid 23115626)
78. Vietri NJ, Purcell BK, Lawler JV, et al. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci USA 2006;103(20):7813-7816.
79. Lincoln R, Klein F, Walker J, et al. Successful treatment of rhesus monkeys for septicemia anthrax. Antimicrob Agents Chemother 1964;10:759-763.
80. US Centers for Disease Control and Prevention. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2002;51(45):1024-1026.
81. Fowler GF, Baggs JM, Weintraub ES, Martin SW, McNeil NN, Gust DA. Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's Anthrax Vaccination Program. Pharmacoepidemiol Drug Saf 2006;15(12): 880-888. (Pubitemid 44941641)